3rd generation glp 1 agonist GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease PDB-101: Molecule of the Month:

C., Allen B

37% achieved 20% weight loss, indicating a magnitude of effect greater than that typically observed with earlier pharmacotherapies for obesity

Y.YangC

By purchasing, you confirm that you are a qualified individual using this product in accordance with all applicable laws and research regulations

Currency volatility and lower health-care spend slow penetration, yet IDFs prevalence forecast suggests eventual policy shifts once biosimilar prices sink

Abstract This article examines the growing prevalence of pediatric obesity and its connection to metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents, focusing on the role of glucagon-like peptide-1 receptor agonists in treatment